cervical persistent high-risk HPV infection
Conditions
Interventions
Experimental group:Ultrasonic gynecological therapy instrument
Control group:None
Sponsors
Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
Female
Age
25 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Women aged 25-65 with a sexual history; 2. Patients identified by cervical HPV-DNA testing as high-risk human papillomavirus (HPV) infection with a history of at least 6 months of infection with at least one high-risk HPV subtype; 3. Patients who are willing to provide written informed consent, or whose legally authorized guardian is able to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Women with pregnancy plan during pregnancy, lactation period or within half a year; 2. Patients who have received interferon therapy in the last 10 days; 3. Patients who have received cervical physical therapy or cervical surgery within the last 3 months; 4. Patients who have received HPV vaccination in the last 6 months; 5. Patients with other diseases of the reproductive system requiring immediate treatment; 6. Patients with severe heart, brain, respiratory system diseases, liver and kidney insufficiency, coagulopathy, severe anemia or diabetes that cannot be controlled by drugs; 7. Syphilis, AIDS or other sexually transmitted diseases; 8. Cervical histopathological examination of >= high intraepithelial lesions (HSIL), including squamous or glandular epithelial origin; 9. Participated in other clinical trials within 30 days; 10. The investigator did not consider it appropriate to participate in this clinical trial for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall effective efficiency of cervical high-risk HPV clearance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vaginal bleeding;Incidence rate of device failure;Incidence rate of adverse event and serious adverse event; | — |
Countries
China
Contacts
Public ContactYang Bing
Outcome results
None listed